Vetter works towards a sustainable energy supply

The Center for Visual Inspection and Logistics in Ravensburg which recently was awarded as a Facility of the Future, applies modern workflows and a sustainable energy concept. (Source: Vetter Pharma International GmbH.)
All German sites of the pharmaceutical service provider will be supplied with green electricity.
Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from certified renewable energy sources.
As a partner of biotechnology and pharmaceutical customers both large and small, Vetter has been meeting high international sustainability requirements for many years. The company is certified according to the standards for environmental protection ISO 14001, energy management ISO 50001, as well as occupational health and safety BS OHSAS 18001.
“Sustainability is a central pillar of Vetter’s corporate philosophy and our stance on this subject is firmly anchored within our organization. The supply of our German sites with green electricity is an important part of our company-wide program for environmental protection, energy management, and occupational health and safety,” explains Managing Director Thomas Otto. “Our aim is to act holistically and develop our multi-faceted initiatives in these areas on a continuous basis.”
The next milestone has already been set. Within the next 10 years, Vetter plans to offset the company-wide use of natural gas, making it completely CO2 neutral. Unavoidable CO2 emissions are offset by investments in high-quality climate protection projects.
The largest sustainability project the CDMO recently implemented is at its state-of-the-art center for visual inspection and logistics, which received the international industry prize Facility of the Year Award (FOYA) in 2018 as a Facility of the Future. The site consequently realizes a sustainable energy concept specifically developed by Vetter. This includes the operation of a modern, environmentally friendly block heating and power plant, the use of geothermal energy and the comprehensive use of excess energy, as well as powerful photovoltaic systems, all of which are combined in an energy-efficient manner.
The company-wide EHS program also includes actions for sustainable, resource-efficient management, the promotion of healthy working conditions, and regular training for all staff members to raise their individual awareness of responsible behaviour.

Related News
-
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers? -
News Eli Lilly, Novo Nordisk, and Sanofi cut insulin prices by up to 78%
Insulin prices have dropped in a stark play by the three biggest makers of the product, after calls from the top of the US government. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Open letter challenges EU Commission on medicine supply chain
In an open letter to the European Commission, Medicines for Europe calls for a new medicine security contract with their goal to improve access to medicine and ensure a secure supply chain to Europe. -
News The Biggest Drug Approvals of 2022
A carefully curated list of the most notable drug approvals of the past year, covering neurology, oncology, and COVID-19, as well as a look at the most promising drugs up for review in 2023. -
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance